Navigation Links
Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP,by Department of Health and Human Services

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it was informed late Wednesday, March 07, 2007, by the Department of Health & Human Services (HHS) that NEUMUNE(R), the Company's product candidate for the treatment of Acute Radiation Syndrome (ARS) was found technically unacceptable and was no longer in the competitive range for the Request for Proposal (RFP) No. DHHS-ORDC-DDA-05-12 entitled, "Medical Countermeasures to Mitigate or Treat Neutropenia Alone or in Combination with Co-Morbidities Associated with Acute Radiation Syndrome (ARS)." No other rationale was provided. Further, Hollis-Eden was notified that HHS had cancelled the solicitation in its entirety.

The Company was surprised by this decision by HHS. In June 2006, based on HHS' evaluation of the Company's technical and cost proposal, HHS informed the Company that its proposal for NEUMUNE was within the competitive range. HHS reaffirmed this decision in October 2006, and Hollis-Eden believes that as of that time its proposal was the only proposal still being considered by HHS. Since that time, HHS has not requested any additional safety or efficacy data on NEUMUNE that had not previously been provided in detailed or summary form. Therefore, the Company is unable to comprehend how NEUMUNE can no longer meet the technical requirements of the solicitation.

"Given the nature and stage of our communications with HHS regarding our original ARS proposal and subsequent revisions, this decision by HHS to exclude our proposal and cancel the RFP is shocking and difficult to understand," stated Richard B. Hollis, Chairman and Chief Executive Officer of Hollis-Eden. "While we will attempt to gain a better understanding from HHS why this determination was made, we clearly met all of the very detailed requirements of the solicitation. NEUMUNE is the only agent ever to have shown the ability to
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/21/2013)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a ... it has entered into new agreements covering its supply ... the kidney care division of DaVita Healthcare Partners Inc. ... the use of products for home hemodialysis in ... a second amended and restated National Service Provider Agreement ...
(Date:5/21/2013)... 2013   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... Operating Officer and Executive Vice President, Finance, will present ... Healthcare Conference on Wednesday, May 29, 2013 at 3:30 ... Westin Boston Waterfront Hotel. The presentation will ...
(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 /PRNewswire/ ... new corporate image and impressive new product developments at the ... . "After ten years of unerring focus on product literature ... the need to mark the occasion," said founding director ... have some interesting developments of benefit to our clients and ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3
... CHICAGO, Oct. 28 The non-profit Midwest Business Group ... with numerous local and national organizations, have launched a health ... personal contact to help people improve and manage health conditions. ... ) information series will run through the end of ...
... 28 Amira Pharmaceuticals, Inc. announced today that it ... a novel LPA1 antagonist, in normal, healthy subjects. ... exploring the therapeutic value of AM152, a potentially novel ... safety, pharmacodynamic (PD) and pharmacokinetic (PK) profile of this ...
Cached Medicine Technology:New 'Take Control of Your Health' Education Series to Improve Health of Chicagoans 2Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 2
(Date:5/21/2013)... Paris, France: One-year results from SOURCE XT one ... registries to-date reported today at EuroPCR 2013 show ... rates of device success for all access approaches, valve ... Study followed up 2688 consecutively enrolled patients (mean age ... valve at 93 centres in 17 countries between July ...
(Date:5/21/2013)... stent, which is a novel stent platform eluting ... the Xience Prime everolimus-eluting stent for the primary ... nine months in the results of an imaging ... BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical ... and stent apposition at nine months after treating ...
(Date:5/21/2013)... Arizona State University is seeking ... develop their ideas into solutions, products and services ... university is recruiting participants for AREA48 (Applied Regional ... provides early-stage entrepreneurs with opportunities to access human ... anyone, ASU is particularly seeking participation from retirees, ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... The federal judge overseeing the litigation ... lawsuits in U.S. District Court, Northern District of Georgia, ... from Plaintiffs’ Counsel to conduct Ex Parte interviews with ... Order grants that request, and sets forth procedures under ... Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... cuts readmissions , , WEDNESDAY, May 6 (HealthDay News) -- ... airway pressure (CPAP) may help improve outcomes in patients ... CPAP is commonly used to treat sleep apnea. ... Chest , included 232 cardiac surgery patients who ...
... Former McKesson executive to lead further innovation of ... government agencies and wellness companiesBEDFORD, Mass., May 6 ... management software solutions, today announced that Bill Wisotzkey ... and design, effective immediately. Wisotzkey has more than ...
... outbreak in Mexico, the Foreign and Commonwealth Office (FCO) is advising against ... it will consider all claims for cancelled holidays to the country, scheduled ... ... (PRWEB) -- In the wake of the swine flu outbreak in Mexico, ...
... PHILADELPHIA, May 6 The Mobile Massage Team ( ... services for corporate wellness programs, promotional events, and special affairs, ... exhibitor at the 3rd Annual GlobalFit Worksite Wellness Summit ( ... 14, 2009 at The Down Town Club in Center City ...
... conference focused on promoting physical activity on college ... on connecting health care providers and the public ... infiltrating college campuses nationwide. The American College of ... On Campus," a program component to address and ...
... Against Tobacco Recognized Nationally--WASHINGTON, May 6 ... named Youth Advocates of the Year by the Campaign ... fight against tobacco. Members of REAL are being honored ... the nation,s capital tonight (May 6) along with a ...
Cached Medicine News:Health News:Casenet Names Bill Wisotzkey Vice President of Product Management and Design 2Health News:Sainsbury's Travel Insurance will Consider Claims for Cancelled Holidays to Mexico 2Health News:Sainsbury's Travel Insurance will Consider Claims for Cancelled Holidays to Mexico 3Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 2Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 3Health News:Campaign for Tobacco-Free Kids Honors REAL of Hawai'i As Youth Advocates of the Year 2
Jayle tying forceps, straight....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Gerl titanium tying forceps has curved shanks, smooth jaws and 6 mm long tying platform. For 8-0 to 11-0 sutures....
Harms tying forceps, standard, straight with smooth jaws. For 7-0 to 9-0 sutures....
Medicine Products: